Immune Response News and Research

RSS

Immune system differences, better blood vessel health could protect children from severe COVID-19

Differences in the immune systems and better blood vessel health were among the factors protecting children from severe COVID-19, according to a new review.

2 Dec 2020

Scientists identify mechanisms behind inflammasome activation by fungal pathogens

Scientists at St. Jude Children's Research Hospital have identified the mechanisms behind inflammasome activation driven by infection with the fungal pathogen Aspergillus fumigatus.

2 Dec 2020

The UK approves Pfizer vaccine for December 2020 roll out

The UK approves Pfizer vaccine and schedules phased vaccination process, commencing December 2020.

2 Dec 2020

SARS-CoV-2 D614G mutation does not affect performance of serological assays

In a new study published in The Journal of Infectious Diseases, US researchers considered the emergence of a new SARS-CoV-2 spike protein variant. They compared spike G614-based assay to the original D614-based assay – pointing towards the development of recognizable, cross-responsive humoral immunity.

2 Dec 2020

A new potential COVID-19 vaccine candidate: YF-S0

A recent study published in the journal Nature describes the safety and efficacy of a live-attenuated yellow fever 17D (YF17D) vector-based vaccine candidate expressing a non-cleavable form of the spike protein of severe acute respiratory coronavirus 2 (SARS-CoV2).

2 Dec 2020

New and sudden headaches may be a symptom of COVID-19

Researchers report a case of a young male patient who came in with a headache to an emergency room. He had increased intracranial pressure and tested positive for SARS-CoV-2, suggesting new headaches during the pandemic should not be ignored.

2 Dec 2020

CNRS develops new patented technique that reveals energy status of cells

A procedure that may help personalise anticancer therapies has just been developed by the CNRS, INSERM, and Aix-Marseille University scientists at the Centre d'Immunologie de Marseille-Luminy, in association with colleagues from the University of California San Francisco and the Marseille Public University Hospital System (AP-HM), with support from Canceropôle Provence-Alpes-Côte d'Azur.

2 Dec 2020

Researchers evaluate the most appropriate test for COVID-19

Until a vaccine is available, curbing the coronavirus pandemic relies heavily on how quickly a potentially exposed individual can be tested and quarantined.

2 Dec 2020

Researchers study SerpinB9 protein that could pave way to new immunotherapy approach

Immunotherapies have transformed the landscape of cancer treatment by allowing physicians to alter or augment patients' immune response to better attack malignant tumors.

2 Dec 2020

PTC299 inhibits SARS-CoV-2 replication and suppresses production of inflammatory cytokines

In an article published in the journal Virus Research, a team of researchers from various US institutions discussed their study that evaluated the antiviral activity of PTC299 against a group of RNA viruses in vitro.

1 Dec 2020

Nanomedicine's giant step into the fight against the COVID-19

A recent editorial in Nature Nanotechnology discusses the enormous feat of scientific innovation, with messenger RNA (mRNA)-based vaccines developed to deliver the gene sequence of specific SARS-CoV-2 viral proteins into host cells using nanotechnology platforms.

1 Dec 2020

Research suggests plant flavonols could serve as effective antivirals for SARS-CoV-2

Researchers in Algeria have reviewed some of the evidence suggesting that flavonols commonly found in many plants and vegetables could be used as a therapeutic approach to coronavirus disease 2019 (COVID-19).

1 Dec 2020

Researchers uncover the role of protein in identifying common cold virus

The role of a protein in detecting the common cold virus and kickstarting an immune response to fight infection has been uncovered by a team of scientists from Nanyang Technological University, Singapore (NTU Singapore), the Agency for Science, Technology and Research (A*STAR) and the National University of Singapore.

1 Dec 2020

Low endorsement among doctors worldwide for COVID-19 ‘immunity passports’

A cross-sectional survey conducted in September 2020, aimed at assessing the views of a randomly selected, stratified physician sample on this matter, drawing names from physicians registered with the global networking platform called Sermo. This offers its registration service to verified licensed physicians.

1 Dec 2020

New reviews provide timely updates for scholars, professionals focused on antimicrobial research

The initial chapter of 'Anti-infective Research and Development: Updates on Infection Mechanisms and Treatments' covers the mode of action of natural antimycobacterial compounds such as nordihydroguaiaretic acid, α-mangostin and allicin, as well as antimicrobial peptides and their role in the innate and adaptive immune response leading to the decrease of microbial resistance.

1 Dec 2020

Wyss Institute’s eRapid technology licensed to The iQ Group Global

Today, the Wyss Institute for Biologically Inspired Engineering at Harvard University announced that its eRapid technology has been licensed to The iQ Group Global for COVID-19 diagnostic applications.

30 Nov 2020

SARS-CoV-2 immunity in the U.S. remains low

Seroprevalence studies indicate that less than 10% of people in the U. S. have detectable antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from July to September 2020.

30 Nov 2020

Virus induced lymphocytes show promise for COVID-19 and future pandemics

Researchers in the United States have conducted a study demonstrating the potential of a novel therapeutic approach to treating coronavirus disease 2019 (COVID-19). The therapy augments the body’s T cell response to the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by providing a boost of rapidly expanded virus-specific T cells.

30 Nov 2020

Highly functional immune response in asymptomatic SARS-CoV-2 infection

Researchers in Singapore have conducted a study showing that asymptomatic individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – mount an efficient, balanced and coordinated cellular immune response that protects the host without appearing to trigger any pathological processes.

30 Nov 2020